{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:37:15Z","timestamp":1793194635870,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13014-019-1346-5","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T13:05:59Z","timestamp":1564751159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes"],"prefix":"10.1186","volume":"14","author":[{"given":"Mark E.","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Mayeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Liz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Goode-Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissette","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Elliston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine S.","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar A.","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Wenske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"1346_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5306\/wjco.v8.i5.389","volume":"8","author":"YA Syed","year":"2017","unstructured":"Syed YA, Patel-Yadav AK, Rivers C, Singh AK. Stereotactic radiotherapy for prostate cancer: a review and future directions. World J Clin Oncol. 2017;8:389\u201397.","journal-title":"World J Clin Oncol"},{"key":"1346_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fonc.2015.00048","volume":"5","author":"R Meier","year":"2015","unstructured":"Meier R. Dose-escalated robotic SBRT for stage II prostate cancer. Front Oncol. 2015;5:48.","journal-title":"Front Oncol"},{"key":"1346_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","volume":"109","author":"CR King","year":"2013","unstructured":"King CR, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109:217\u201321.","journal-title":"Radiother Oncol"},{"key":"1346_CR4","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1002\/cncr.30034","volume":"122","author":"BR Baker","year":"2016","unstructured":"Baker BR, Basak R, Mohiuddin JJ, Chen RC. Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012: SBRT use for prostate Cancer. Cancer. 2016;122:2234\u201341.","journal-title":"Cancer"},{"key":"1346_CR5","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","volume":"67","author":"BL Madsen","year":"2007","unstructured":"Madsen BL, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results. Int J Radiat Oncol. 2007;67:1099\u2013105.","journal-title":"Int J Radiat Oncol"},{"key":"1346_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","volume":"82","author":"CR King","year":"2012","unstructured":"King CR, Brooks JD, Gill H, Presti JC. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate Cancer. Int J Radiat Oncol Biol Phys. 2012;82:877\u201382.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1346_CR7","doi-asserted-by":"publisher","first-page":"S393","DOI":"10.1016\/j.ijrobp.2013.06.1030","volume":"87","author":"CA Mantz","year":"2013","unstructured":"Mantz CA, Fernandez E. Real-time target tracking prostate SBRT and the real-time tracking system 4D localization system: 5-year quality of life and disease outcomes. Int J Radiat Oncol Biol Phys. 2013;87:S393.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1346_CR8","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.ijrobp.2013.06.071","volume":"87","author":"D Loblaw","year":"2013","unstructured":"Loblaw D, et al. Comparison of biochemical and toxicity outcomes from a contemporaneous cohort study of low-risk prostate cancer treated with different radiation techniques. Int J Radiat Oncol Biol Phys. 2013;87:S26.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1346_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3389\/fonc.2017.00157","volume":"7","author":"S Kataria","year":"2017","unstructured":"Kataria S, et al. Prostate-specific antigen 5 years following stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: an ablative procedure? Front Oncol. 2017;7:157.","journal-title":"Front Oncol"},{"issue":"1","key":"1346_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","volume":"104","author":"Michael J. Zelefsky","year":"2019","unstructured":"Zelefsky MJ, et al. 5-year outcomes of a phase I dose escalation study using stereotactic body radiosurgery for patients with low and intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2019. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2018.12.045\n                    \n                  .","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"1346_CR11","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.ijrobp.2016.06.094","volume":"96","author":"R Meier","year":"2016","unstructured":"Meier R, et al. Five-year outcomes from a multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate Cancer. Int J Radiat Oncol Biol Phys. 2016;96:S33\u20134.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1346_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","volume":"102","author":"RM Meier","year":"2018","unstructured":"Meier RM, et al. Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys. 2018;102:296\u2013303.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1346_CR13","doi-asserted-by":"publisher","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","volume":"2","author":"AU Kishan","year":"2019","unstructured":"Kishan AU, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate Cancer. JAMA Netw Open. 2019;2:e188006.","journal-title":"JAMA Netw Open"},{"key":"1346_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0936-6555(05)80831-3","volume":"3","author":"CD Collins","year":"1991","unstructured":"Collins CD, Lloyd-Davies RW, Swan AV. Radical external beam radiotherapy for localised carcinoma of the prostate using a Hypofractionation technique. Clin Oncol (R Coll Radiol). 1991;3:127\u201332.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1346_CR15","doi-asserted-by":"publisher","unstructured":"Katz A. Stereotactic body radiotherapy for low-risk prostate Cancer: a ten-year analysis. Cureus. 2017. \n                    https:\/\/doi.org\/10.7759\/cureus.1668\n                    \n                  .","DOI":"10.7759\/cureus.1668"},{"key":"1346_CR16","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ijrobp.2014.03.012","volume":"89","author":"DWN Kim","year":"2014","unstructured":"Kim DWN, et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014;89:509\u201317.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1346_CR17","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/cncr.30101","volume":"122","author":"JA Halpern","year":"2016","unstructured":"Halpern JA, et al. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer: SBRT for localized prostate cancer. Cancer. 2016;122:2496\u2013504.","journal-title":"Cancer"},{"key":"1346_CR18","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1200\/JCO.2013.53.8652","volume":"32","author":"JB Yu","year":"2014","unstructured":"Yu JB, et al. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate Cancer: comparison of toxicity. J Clin Oncol. 2014;32:1195\u2013201.","journal-title":"J Clin Oncol"},{"key":"1346_CR19","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","volume":"97","author":"DA Hamstra","year":"2017","unstructured":"Hamstra DA, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97:976\u201385.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1346_CR20","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/j.clon.2016.05.005","volume":"28","author":"D Whalley","year":"2016","unstructured":"Whalley D, Hruby G, Alfieri F, Kneebone A, Eade T. SpaceOAR hydrogel in dose-escalated prostate Cancer radiotherapy: rectal dosimetry and late toxicity. Clin Oncol. 2016;28:e148\u201354.","journal-title":"Clin Oncol"},{"key":"1346_CR21","doi-asserted-by":"publisher","first-page":"20140736","DOI":"10.1259\/bjr.20140736","volume":"88","author":"R Ruggieri","year":"2015","unstructured":"Ruggieri R, et al. Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. Br J Radiol. 2015;88:20140736.","journal-title":"Br J Radiol"},{"key":"1346_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.meddos.2017.07.002","volume":"42","author":"RT Jones","year":"2017","unstructured":"Jones RT, et al. Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. Med Dosim. 2017;42:341\u20137.","journal-title":"Med Dosim"},{"key":"1346_CR23","doi-asserted-by":"publisher","first-page":"291.e19","DOI":"10.1016\/j.urolonc.2016.02.024","volume":"34","author":"RC Hutchinson","year":"2016","unstructured":"Hutchinson RC, Sundaram V, Folkert M, Lotan Y. Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications. Urol Oncol Semin Orig Investig. 2016;34:291.e19\u201326.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"1346_CR24","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","volume":"64","author":"ZS Zumsteg","year":"2013","unstructured":"Zumsteg ZS, et al. A new risk classification system for therapeutic decision making with intermediate-risk prostate Cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013;64:895\u2013902.","journal-title":"Eur Urol"},{"key":"1346_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","volume":"59","author":"R Hannan","year":"2016","unstructured":"Hannan R, et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer\u2014results from a multi-institutional clinical trial. Eur J Cancer. 2016;59:142\u201351.","journal-title":"Eur J Cancer"},{"key":"1346_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13014-018-1135-6","volume":"13","author":"ME Hwang","year":"2018","unstructured":"Hwang ME, et al. A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy. Radiat Oncol. 2018;13:192.","journal-title":"Radiat Oncol"},{"key":"1346_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.radonc.2013.03.022","volume":"107","author":"A Loblaw","year":"2013","unstructured":"Loblaw A, et al. Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes. Radiother Oncol. 2013;107:153\u20138.","journal-title":"Radiother Oncol"},{"key":"1346_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2490-10-1","volume":"10","author":"AJ Katz","year":"2010","unstructured":"Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10:1.","journal-title":"BMC Urol"},{"key":"1346_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1748-717X-8-58","volume":"8","author":"LN Chen","year":"2013","unstructured":"Chen LN, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013;8:58.","journal-title":"Radiat Oncol"},{"key":"1346_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s13014-018-1182-z","volume":"13","author":"Y Park","year":"2018","unstructured":"Park Y, et al. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15\u201301). Radiat Oncol. 2018;13:230.","journal-title":"Radiat Oncol"},{"key":"1346_CR31","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1002\/cncr.26699","volume":"118","author":"SM McBride","year":"2012","unstructured":"McBride SM, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012;118:3681\u201390.","journal-title":"Cancer"},{"key":"1346_CR32","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.21037\/cco.2017.06.05","volume":"6","author":"W Haque","year":"2017","unstructured":"Haque W, Butler EB, Teh BS. Stereotactic body radiation therapy for prostate cancer\u2014a review. Chin Clin Oncol. 2017;6:S10.","journal-title":"Chin Clin Oncol"},{"key":"1346_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1471-2490-13-49","volume":"13","author":"G Bolzicco","year":"2013","unstructured":"Bolzicco G, et al. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy. BMC Urol. 2013;13:49.","journal-title":"BMC Urol"},{"key":"1346_CR34","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","volume":"1","author":"DB Fuller","year":"2018","unstructured":"Fuller DB, et al. Phase 2 multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate Cancer: 5-year outcomes. Eur Urol Oncol. 2018;1:540\u20137.","journal-title":"Eur Urol Oncol"},{"key":"1346_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0360-3016(01)01601-7","volume":"51","author":"PD Grimm","year":"2001","unstructured":"Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol. 2001;51:31\u201340.","journal-title":"Int J Radiat Oncol"},{"key":"1346_CR36","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.ijrobp.2010.11.049","volume":"82","author":"KA Hinnen","year":"2012","unstructured":"Hinnen KA, et al. Prostate specific antigen bounce is related to overall survival in prostate brachytherapy. Int J Radiat Oncol. 2012;82:883\u20138.","journal-title":"Int J Radiat Oncol"},{"key":"1346_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijrobp.2017.09.003","volume":"100","author":"PB Romesser","year":"2018","unstructured":"Romesser PB, et al. Prostate-specific antigen (PSA) bounce after dose-escalated external beam radiation therapy is an independent predictor of PSA recurrence, metastasis, and survival in prostate adenocarcinoma patients. Int J Radiat Oncol Biol Phys. 2018;100:59\u201367.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1346_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.urology.2006.09.017","volume":"69","author":"M Pinkawa","year":"2007","unstructured":"Pinkawa M, et al. Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy. Urology. 2007;69:129\u201333.","journal-title":"Urology"},{"key":"1346_CR39","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/annonc\/mdp365","volume":"21","author":"R de Crevoisier","year":"2010","unstructured":"de Crevoisier R, et al. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy. Ann Oncol. 2010;21:808\u201314.","journal-title":"Ann Oncol"},{"key":"1346_CR40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ijrobp.2012.04.009","volume":"85","author":"M Foo","year":"2013","unstructured":"Foo M, Lavieri M, Pickles T. Impact of neoadjuvant prostate-specific antigen kinetics on biochemical failure and prostate Cancer mortality: results from a prospective patient database. Int J Radiat Oncol Biol Phys. 2013;85:385\u201392.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1346_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.radonc.2015.07.016","volume":"116","author":"JR Evans","year":"2015","unstructured":"Evans JR, et al. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol. 2015;116:179\u201384.","journal-title":"Radiother Oncol"},{"key":"1346_CR42","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.radonc.2016.10.013","volume":"121","author":"SB Johnson","year":"2016","unstructured":"Johnson SB, et al. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol. 2016;121:294\u20138.","journal-title":"Radiother Oncol"},{"key":"1346_CR43","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.ijrobp.2015.04.030","volume":"92","author":"N Mariados","year":"2015","unstructured":"Mariados N, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: Dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015;92:971\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1346_CR44","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","volume":"43","author":"DJ Brenner","year":"1999","unstructured":"Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095\u2013101.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1346_CR45","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.ijrobp.2015.02.046","volume":"92","author":"G Bauman","year":"2015","unstructured":"Bauman G, et al. A phase 1\/2 trial of brief androgen suppression and stereotactic radiation therapy (FASTR) for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2015;92:856\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1346_CR46","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","volume":"102","author":"Hima Bindu Musunuru","year":"2018","unstructured":"Musunuru HB, et al. Phase I\/II study of stereotactic ablative radio therapy Including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): early toxicity and quality of life. Int J Radiat Oncol Biol Phys. 2018. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2018.07.2005\n                    \n                  .","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"1346_CR47","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.clon.2018.03.004","volume":"30","author":"V Murthy","year":"2018","unstructured":"Murthy V, et al. Early results of extreme hypofractionation using stereotactic body radiation therapy for high-risk, Very High-risk and Node-positive Prostate Cancer. Clin Oncol. 2018;30:442\u20137.","journal-title":"Clin Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1346-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-019-1346-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-019-1346-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T08:51:21Z","timestamp":1596271881000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-019-1346-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1346"],"URL":"https:\/\/doi.org\/10.1186\/s13014-019-1346-5","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"24 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Retrospective chart review of patients with prostate cancer was conducted from our single-institution IRB-approved database # AAAQ8136.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}